Immunovant (IMVT) Stock Statistics & Valuation Metrics

Immunovant has a market cap or net worth of $2.65B. The enterprise value is $2.14B.

Immunovant has 174,316,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunovant’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -62.06%.

The current PE Ratio of Immunovant is ―. Immunovant’s PEG ratio is ―.

In the last 12 months, Immunovant had revenue of 0.00 and earned -413.84M in profits. Earnings per share was -2.73.

In the last 12 months, operating cash flow was -417.09M and capital expenditures -577.00K, giving a free cash flow of -417.66M billion.

Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―

Immunovant upcoming earnings date is Oct 31, 2025, Before Open (Confirmed).

Immunovant as a current ratio of 11.16, with Debt / Equity ratio of 0.00%

In the past 12 months, Immunovant has paid 891.00K in taxes.

Immunovant EV to EBITDA ratio is -4.55, with an EV/FCF ratio of -4.98.

Immunovant has $598.91M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$598.91M billion.

Gross margin is -134.38%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immunovant is $37.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy